InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Forms New Scientific Advisory Board
October 21, 2020

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Forms New Scientific Advisory Board

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins, has announced  the formation of a Scientific Advisory Board (“SAB”) designed to provide the company with invaluable expertise and insights. The company also announced that three leading global experts in exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis have been appointed to the board: Michael Konstan, MD; Darwin L. Conwell, MD; and Michael Wilschanski, MD. Konstanis vice dean for translational research and the Gertrude Lee Chandler Tucker Professor of Pediatrics at Case Western Reserve University School of Medicine; he is also the Austin Ricci chair in pediatric pulmonary care and research at University Hospitals Rainbow Babies and Children’s Hospital in Cleveland, Ohio. Konstan has spent his entire professional career in the care and research of people with cystic fibrosis (“CF”). Conwell is a gastroenterology physician-scientist specializing in pancreas disorders and is a professor of medicine at The Ohio State University College of Medicine where he serves as director of the Division of Gastroenterology, Hepatology and Nutrition at The Ohio State Wexner Medical Center. He is an NIH-funded physician-scientist with over 200 peer reviewed publications. The leader of numerous national and international studies of potentially new therapies in CF, Wilschanski is director of pediatric gastroenterology at Hadassah Hebrew University Medical Center. In addition, he also serves as the director of the Electrophysiology Laboratory in Hadassah where he performs in vivo and in vitro measurements of electrolyte transport, which is used diagnostically and therapeutically in CF. “We are thrilled to have this distinguished group of scientific leaders helping to guide our research and clinical development efforts as we advance our MS1819 program for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis patients,” said AzurRx CEO James Sapirstein in the press release.

To view the full press release, visit https://ibn.fm/zHDzY

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specializing in the research and development of nonsystemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care.  The company is headquartered in New York, NY, with scientific operations based in Langlade, France, and clinical operations in Hayward, California. For more information about the company, visit www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).